Published in World J Urol on January 01, 1996
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
Chemistry and structural biology of androgen receptor. Chem Rev (2005) 1.72
Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. Am J Pathol (2002) 1.41
The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol (2005) 1.19
Identification and characterization of ART-27, a novel coactivator for the androgen receptor N terminus. Mol Biol Cell (2002) 1.11
Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol (1998) 1.10
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer (1999) 0.93
Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect (1999) 0.83
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013) 0.82
The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem (1986) 2.07
The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem (1980) 1.66
Gender differences in stage-adjusted bladder cancer survival. Urology (2000) 1.55
Molecular detection of primary bladder cancer by microsatellite analysis. Science (1996) 1.44
Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer (1991) 1.39
Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A (1992) 1.28
Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer (1993) 1.24
The relationship of the nuclear matrix to cellular structure and function. Adv Enzyme Regul (1978) 1.23
Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol (1992) 1.21
Genetic alterations in urinary bladder carcinosarcoma: evidence of a common clonal origin. Eur Urol (2000) 1.18
Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin Cancer Res (1997) 1.14
Estrogen receptors in human prostate: evidence for multiple binding sites. J Clin Endocrinol Metab (1983) 1.14
Partial allelotype of carcinoma in situ of the human bladder. Cancer Res (1995) 1.09
Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res (1995) 1.07
Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med (1997) 1.07
The nuclear matrix of the prostate contains acceptor sites for androgen receptors. Endocrinology (1983) 1.05
Novel suppressor loci on chromosome 14q in primary bladder cancer. Cancer Res (1995) 0.98
Renal artery pseudoaneurysm occurring after partial nephrectomy. Urology (2001) 0.97
Correlation of cystoscopic impression with histologic diagnosis of biopsy specimens of the bladder. Hum Pathol (2001) 0.96
Successful conservative management of perforated ileal neobladder. J Urol (2001) 0.95
Expression of transforming growth factor-beta 1 in prostate cancer. Endocrinology (1994) 0.95
Concepts related to salt resistant estradiol receptors in rat uterine nuclei: nuclear matrix. Biochem Biophys Res Commun (1977) 0.95
Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res (1995) 0.92
Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer (2000) 0.90
The regulation of nuclear DNA template restrictions by acidic polymers. Adv Enzyme Regul (1974) 0.90
Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy. Cancer (1991) 0.89
Biological properties of the nuclear matrix: steroid hormone binding. Recent Prog Horm Res (1982) 0.89
Human papillomavirus associated with bladder cancer. Urology (1992) 0.87
Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun (1994) 0.86
Immunogold probes for electron microscopy: evaluation of staining by fluorescence microscopy. J Histochem Cytochem (1985) 0.86
Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res (1983) 0.85
The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines. J Urol (1984) 0.84
Sexually dimorphic expression of estrogen receptors, but not of androgen receptors in human fetal external genitalia. J Clin Endocrinol Metab (1993) 0.84
Clinical significance of denuded urothelium in bladder biopsy. J Urol (2001) 0.83
Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients. Int J Cancer (1997) 0.82
Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy. Cancer Surv (1991) 0.80
Estrogen receptors in the nuclear matrix: direct demonstration using monoclonal antireceptor antibody. Endocrinology (1987) 0.80
Mitogenesis in normal human fibroblasts by polyinosinic . polycytidylic acid and other synthetic acidic polymers: enhancement of action by glucocorticoids. J Cell Physiol (1981) 0.80
Simultaneous measurement of progesterone and androgen receptors in human prostate: a microassay. J Clin Endocrinol Metab (1982) 0.80
Immunocytochemical localization of estrogen receptors in the normal male and female canine urinary tract and prostate. Endocrinology (1987) 0.79
The relationship of cellular structure and function: the matrix system. Prog Clin Biol Res (1981) 0.78
Affinity chromatography of steroid-transforming enzymes. Methods Enzymol (1974) 0.78
DNA synthesis in the canine prostate: effects of androgen and estrogen treatment. Prostate (1987) 0.77
Androgen receptor localization in the human prostate: demonstration of heterogeneity using a new method of steroid receptor autoradiography. J Steroid Biochem (1987) 0.77
Induction of proteins in human lymphoblastoid cells by recombinant alpha interferon. J Interferon Res (1984) 0.77
Familial transitional cell carcinoma among the population of Iceland. J Urol (1997) 0.77
Absence of karyotype abnormalities in patients with familial urothelial cell carcinoma. Urology (2001) 0.77
Effects of transforming growth factor beta 1 on the adenylyl cyclase-cAMP pathway in prostate cancer. Growth Factors (1994) 0.76
Microsatellite deoxyribonucleic acid analysis to detect bladder cancer in bladder exstrophy. J Urol (1998) 0.76
Extensive squamous cell carcinoma in situ of the bladder masking deeply invasive disease. J Urol (1998) 0.75
The specific binding of estradiol to the nuclear matrix. Adv Exp Med Biol (1979) 0.75
Anterior bladder tube for continence in neurogenic bladder. Experimental study. Urology (1975) 0.75
A new method for labeling and autoradiographic localization of androgen receptors. J Histochem Cytochem (1987) 0.75
Biological pathways to bladder carcinogenesis. Semin Urol Oncol (2000) 0.75
Testicular metastasis of transitional cell carcinoma of the prostate. J Urol (2000) 0.75
Paclitaxel-induced stomal neuropathy: a unique cause of pain in a patient with ileal conduit. Urology (2000) 0.75
Immunocytochemical localization of estrogen receptors in spontaneous and experimentally induced canine benign prostatic hyperplasia. Prostate (1987) 0.75